Secukinumab Efficacy Without the Initial Loading Dose in Patients With Psoriasis

NCT03828643 · clinicaltrials.gov ↗

COMPLETED

Status

156

Enrollment

OTHER

Sponsor class

Conditions

Psoriasis Vulgaris

Interventions

DRUG: Secukinumab
DRUG: Secukinumab

Sponsor

Universita di Verona